These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 15577034

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
    Ogata H, Koiwa F, Shishido K, Kinugasa E.
    Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
    Pai AB, Smeeding JE, Brook RA.
    Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
    [Abstract] [Full Text] [Related]

  • 8. [Evaluation of coronary artery calcification in ESRD patients].
    Yokoyama K.
    Clin Calcium; 2004 Jun; 14(6):109-15. PubMed ID: 15577064
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [New aspects in the management of renal osteodystrophy].
    Matuszkiewicz-Rowińska J.
    Pol Arch Med Wewn; 2004 Oct; 112 Spec No():89-97. PubMed ID: 15669206
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The clinical management of hyperphosphatemia.
    Ritz E.
    J Nephrol; 2005 Oct; 18(3):221-8. PubMed ID: 16013007
    [Abstract] [Full Text] [Related]

  • 15. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
    Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E.
    Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
    [Abstract] [Full Text] [Related]

  • 16. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.
    Nolan CR, Qunibi WY.
    Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):373-9. PubMed ID: 12815333
    [Abstract] [Full Text] [Related]

  • 17. [K/DOQI clinical practice guidelines for management of renal osteodystrophy in predialysis patients].
    Okada N, Tsubakihara Y.
    Clin Calcium; 2004 May; 14(5):698-706. PubMed ID: 15577030
    [Abstract] [Full Text] [Related]

  • 18. Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification.
    Braun J, Asmus HG, Holzer H, Brunkhorst R, Krause R, Schulz W, Neumayer HH, Raggi P, Bommer J.
    Clin Nephrol; 2004 Aug; 62(2):104-15. PubMed ID: 15356967
    [Abstract] [Full Text] [Related]

  • 19. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats.
    Cozzolino M, Dusso AS, Liapis H, Finch J, Lu Y, Burke SK, Slatopolsky E.
    J Am Soc Nephrol; 2002 Sep; 13(9):2299-308. PubMed ID: 12191974
    [Abstract] [Full Text] [Related]

  • 20. Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial.
    Chertow GM, Dillon MA, Amin N, Burke SK.
    J Ren Nutr; 2000 Jul; 10(3):125-32. PubMed ID: 10921533
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.